Anticancer Activity of Nicotinamide on Lung Cancer

Status Active, not recruiting

Clinical Trial Summary

Nicotinamide is an inhibitor of human sirtuins (HDAC III), and is found to re-activate epigenetically silenced tumor suppressors, RUNX3 (runt-related gene 3) and others, in cancer cells. Nicotinamide was found to be effective in several animal cancer models including lung, bladder, liver, etc. The purpose of this study is to determine whether nicotinamide is also effective in the treatment of human lung cancer.

Clinical Trial Description

The standard therapy to the EGFR (epidermal growth factor receptor) mutation positive non-small-cell lung cancer patients who are not eligible to operation is to administer EGFR-TKIs (tyrosine kinase inhibitors, gefitinib or erlotinib). To determine the effectiveness of nicotinamide on lung cancer, nicotinamide or placebo tablet will be co-administered with gefitinib or erlotinib for two years until the event or censoring occurs. The stratified block randomization was designed with 3 covariates (EGFR mutation status, kind of EGFR-TKI, ECOG (Eastern Cooperative Oncology Group) performance status score variation). The size of lesions will be checked every other months by radiology. PD (progressive disease) will be assessed according to RECIST(Response Evaluation Criteria in Solid Tumors)1.1. After observing 36 events, an interim analysis of hazard ratio by Cox proportional hazard regression will be performed. The final analysis will be done by the same protocol after observation of 72 events. The significance level of the interim and final analysis were set to 0.0075 and 0.0209 respectively. Response rate, quality of life (measured by 10 questions at every visit), and overall survival will be analysed together. All other adverse reactions will be analysed and reported, if there. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02416739
Study type	Interventional
Source	Chungbuk National University
Contact
Status	Active, not recruiting
Phase	Phase 2/Phase 3
Start date	March 2015
Completion date	June 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00985855` - Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer	Phase 2
Completed	`NCT01048645` - Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer	Phase 2
Completed	`NCT00129844` - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer	Phase 2
Completed	`NCT00098085` - Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04995523` - A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC	Phase 1/Phase 2
Completed	`NCT00910676` - Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors	Phase 2
Withdrawn	`NCT00108186` - Celecoxib Treatment for Lung Cancer	Phase 1
Recruiting	`NCT05037825` - The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Recruiting	`NCT00379717` - Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)	Phase 1/Phase 2
Completed	`NCT00404924` - ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures	Phase 3
Completed	`NCT00102505` - A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)	Phase 1
Recruiting	`NCT02905591` - A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC	Phase 2
Active, not recruiting	`NCT03088540` - Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3
Terminated	`NCT00232206` - Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT00271323` - Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients	Phase 2
Completed	`NCT00037817` - Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies	Phase 1
Completed	`NCT03444766` - Study of Nivolumab for Advanced Cancers in India	Phase 4
Completed	`NCT04351334` - Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Completed	`NCT00444015` - Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)	Phase 1
Completed	`NCT00105092` - Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.	Phase 2